Loading stock data…
LRMR
$3.94-0.12 (-2.96%)
Market ClosedLast close May 1
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Larimar Therapeutics, Inc. in the Healthcare sector is trading at $3.94. The stock is currently 39% below its 52-week high of $6.42, remaining 1.5% below its 200-day moving average. Technical signals show oversold RSI of 12 and bearish MACD signal, explaining why LRMR maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 12) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.94
Potential Upside
5%
Whystock Fair Value$4.14
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$16.70+323.9%
Range$7.00 – $26.00
Fundamentals
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clini...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$473.71M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.02
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-44.90%
Volume
Today's trading volume
2.17M
Recent News
Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13
Larimar Therapeutics, Inc. (NASDAQ:LRMR) is one of the 10 Small–Cap Stocks Insiders Are Buying Recently. On March 20, 2026, Wedbush raised the price target on Larimar Therapeutics, Inc. (NASDAQ:LRMR) to $13 from $12 previously and maintained an Outperform rating. Wedbush said the Q4 update was in line with expectations as the company prepares for its […]
Larimar: Q4 Earnings Snapshot
BALA CYNWYD, Pa. AP) — Larimar Therapeutics, Inc. LRMR) on Thursday reported a loss of $62.5 million in its fourth quarter.
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.
Larimar Therapeutics price target raised to $12 from $11 at Wedbush
Wedbush raised the firm’s price target on Larimar Therapeutics (LRMR) to $12 from $11 and keeps an Outperform rating on the shares. The firm notes that last week, the company completed an upsized $100M offering following receipt of Breakthrough Therapy designation for nomlabofusp in Friedreich’s ataxia. After incorporating the raise, Wedbush is also increasing its Q4 spending to tie with year-end 2025 cash $137M. While the firm acknowledges recent FDA decisions have been a source of concern for
Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed?
Larimar Therapeutics recently completed an upsized US$100,000,000 follow-on equity offering at US$5.00 per share, shortly after the FDA granted Breakthrough Therapy Designation to its lead Friedreich’s ataxia candidate, nomlabofusp. This combination of expedited regulatory status and fresh capital raises the company’s capacity to advance nomlabofusp toward planned late-stage development and potential approval milestones. Next, we’ll examine how Breakthrough Therapy Designation for...